During the last session, Bicycle Therapeutics Plc ADR (NASDAQ:BCYC)’s traded shares were 0.47 million, with the beta value of the company hitting 0.89. At the end of the trading day, the stock’s price was $22.71, reflecting an intraday loss of -3.13% or -$0.73. The 52-week high for the BCYC share is $28.67, that puts it down -26.24 from that peak though still a striking 44.78% gain since the share price plummeted to a 52-week low of $12.54. The company’s market capitalization is $1.57B, and the average intraday trading volume over the past 10 days was 0.41 million shares, and the average trade volume was 402.08K shares over the past three months.
Bicycle Therapeutics Plc ADR (BCYC) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.36. BCYC has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.93.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bicycle Therapeutics Plc ADR (NASDAQ:BCYC) trade information
Bicycle Therapeutics Plc ADR (BCYC) registered a -3.13% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.13% in intraday trading to $22.71, hitting a weekly high. The stock’s 5-day price performance is -8.17%, and it has moved by 2.30% in 30 days. Based on these gigs, the overall price performance for the year is 47.95%. The short interest in Bicycle Therapeutics Plc ADR (NASDAQ:BCYC) is 2.92 million shares and it means that shorts have 6.34 day(s) to cover.
The consensus price target of analysts on Wall Street is $55, which implies an increase of 58.71% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $28 and $76 respectively. As a result, BCYC is trading at a discount of -234.65% off the target high and -23.29% off the low.
Bicycle Therapeutics Plc ADR (BCYC) estimates and forecasts
Statistics show that Bicycle Therapeutics Plc ADR has outperformed its competitors in share price, compared to the industry in which it operates. Bicycle Therapeutics Plc ADR (BCYC) shares have gone down -7.61% during the last six months, with a year-to-date growth rate more than the industry average at 37.40% against 17.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 19.80% this quarter and then drop -40.30% in the quarter after that. In the rating firms’ projections, revenue will increase 50.40% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 6.81M as predicted by 12 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 6.48M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 5.33M and 19.53M respectively. In this case, analysts expect current quarter sales to grow by 27.70% and then drop by -66.80% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -12.36%. While earnings are projected to return 40.34% in 2024.
BCYC Dividends
Bicycle Therapeutics Plc ADR is due to release its next quarterly earnings on 2025-Feb-18. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Bicycle Therapeutics Plc ADR (NASDAQ:BCYC)’s Major holders
Bicycle Therapeutics Plc ADR insiders own 0.90% of total outstanding shares while institutional holders control 62.97%, with the float percentage being 63.54%. BAKER BROS. ADVISORS LP is the largest shareholder of the company, while 149.0 institutions own stock in it. As of 2024-06-30, the company held over 9.4 million shares (or 22.0863% of all shares), a total value of $190.26 million in shares.
The next largest institutional holding, with 3.49 million shares, is of DEEP TRACK CAPITAL, LP’s that is approximately 8.2014% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $70.65 million.
